Skip to content
EmergingResearch compoundReference only

AF710B (Trapaxin)

Experimental Alzheimer's drug candidate acting on two brain targets; only early, mostly mouse data exist.

NootropicCholinergicM1 muscarinic PAMSigma-1 agonistAcetylcholineBDNF

Pharmacology

ClassCholinergic · M1 muscarinic PAM · Sigma-1 agonist
Primary targetM1 muscarinic receptor (PAM/agonist)
Targets3 receptor targets
EvidenceReference only
Affected systemsAcetylcholineBDNF

Contents

DETAILED OVERVIEW

What is AF710B (Trapaxin)?

AF710B (Trapaxin) is an investigational drug candidate being researched for the treatment of Alzheimer's disease. It is not approved anywhere and is not sold commercially; in people it may be used only within an approved clinical trial.

It acts on two targets in the brain at once: it gently boosts one receptor of the brain messenger acetylcholine and activates a protein that regulates the cells' stress response. In mouse models of Alzheimer's disease it reduced abnormal changes in a protein called tau, improved cognitive performance and restored signs of healthy connections between nerve cells. Human safety data are scarce, what is known about side effects comes mainly from animal studies and reports, and long-term safety is unknown. It may cause nausea, digestive complaints and increased salivation or sweating, and together with other drugs that boost acetylcholine its effects could add up. There are no human data for pregnancy and breastfeeding.

Mechanism

M1 muscarinic allosteric + σ1 agonist

Half-life

6-8 h (animal PK)

Legal status

Investigational, not approved

Receptor profile

  • M1 muscarinic receptorStrong
  • Sigma-1 receptorModerate
  • Alpha-secretase (APP processing)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Limited human safety data, mostly preclinical (3xTg-AD mouse) and anecdotal reports
  • Possible cholinergic (M1) effects: nausea, GI upset, increased salivation or sweating
  • Vivid dreams, sleep disturbance or headache plausible from cholinergic/sigma-1 modulation
  • Dizziness, headache or impaired coordination possible as central nervous system effects
  • Unknown long-term safety, no validated human dose or route of administration

Contraindications · 5

  • Pregnancy and breastfeeding: no human data, avoid
  • Only within an approved clinical trial, not commercially available; self-medication not advised
  • Risk of additive cholinergic load when combined with cholinergic agents (cholinesterase inhibitors, muscarinic agonists)
  • Anticholinergic drugs may theoretically blunt the effect, co-use warrants caution
  • Extra caution with pre-existing conditions due to unknown interaction and organ (liver/kidney/heart) safety profile

Related Nootropics

Same therapeutic category

FAQ

FAQ

AF710B (Trapaxin) is an experimental drug candidate still in development, being researched mainly as a potential treatment for Alzheimer's disease. It acts on two brain targets at once, with the aim of supporting memory and cognitive function in people affected by the disease, but it's an early-stage development compound, not an established, widely-used nootropic.

Telegram

Have a question about AF710B (Trapaxin)?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC21H29N3OS
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.